These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 1581102)

  • 1. Non-aluminic adynamic bone disease in non-dialyzed uremic patients: a new type of osteopathy due to overtreatment?
    Cohen-Solal ME; Sebert JL; Boudailliez B; Westeel PF; Morinière PH; Marie A; Garabedian M; Fournier A
    Bone; 1992; 13(1):1-5. PubMed ID: 1581102
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disappearance of aluminic bone disease in a long term asymptomatic dialysis population restricting A1(OH)3 intake: emergence of an idiopathic adynamic bone disease not related to aluminum.
    Morinière P; Cohen-Solal M; Belbrik S; Boudailliez B; Marie A; Westeel PF; Renaud H; Fievet P; Lalau JD; Sebert JL
    Nephron; 1989; 53(2):93-101. PubMed ID: 2812179
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Renal osteodystrophy (3); its treatment in dialysis patients].
    Ghitu S; Oprisiu R; Benamar L; Said S; Tataru Albu A; Arsenescu I; el Esper N; Morinière P; Fournier A
    Nephrologie; 2000; 21(8):413-24. PubMed ID: 11213385
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
    Lorenzo Sellares V; Torregrosa V
    Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renal osteodystrophy in dialysis patients: diagnosis and treatment.
    Fournier A; Oprisiu R; Hottelart C; Yverneau PH; Ghazali A; Atik A; Hedri H; Said S; Sechet A; Rasolombololona M; Abighanem O; Sarraj A; El Esper N; Moriniere P; Boudailliez B; Westeel PF; Achard JM; Pruna A
    Artif Organs; 1998 Jul; 22(7):530-57. PubMed ID: 9684690
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of alkaline calcium salts as phosphate binder in uremic patients.
    Fournier A; Morinière P; Ben Hamida F; el Esjer N; Shenovda M; Ghazali A; Bouzernidj M; Achard JM; Westeel PF
    Kidney Int Suppl; 1992 Oct; 38():S50-61. PubMed ID: 1405382
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 1-alpha-Hydroxyvitamin D3 derivatives in the treatment of renal bone diseases: justification and optimal modalities of administration.
    Fournier A; Morinière PH; Oprisiu R; Yverneau-Hardy P; Westeel PF; Mazouz H; el Esper N; Ghazali A; Boudailliez B
    Nephron; 1995; 71(3):254-83. PubMed ID: 8569975
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Prevalence of histological types of bone disease in a hemodialysis center limiting the oral intake of aluminum hydroxide].
    Belbrik S; Marie A; Boudailliez B; Morinière P; Sébert JL; Solal MC; Westeel PF; Roche D; Fournier A
    Nephrologie; 1990; 11(2):83-90. PubMed ID: 2392208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adynamic bone disease in patients with uremia.
    Fournier A; Yverneau PH; Hué P; Said S; Hamdini N; Eldin HM; Mohageb S; Oprisiu R; Marie A; Solal ME
    Curr Opin Nephrol Hypertens; 1994 Jul; 3(4):396-410. PubMed ID: 8076143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renal ostodystrophy during the developing stage of maintenance dialysis in Transylvania. Early development of periarticular calcifications and beta 2 microglobulin amyloidosis in spite of a relatively good prevention of secondary hyperparathyroidism.
    Oprisiu R; Bolosiu H; Boca I; Theodoru C; Elefterescu R; Brazier M; el Esper I; Leflon P; Ledeme C; Fournier A; Heinze V
    Ann Med Interne (Paris); 1998 Mar; 149(2):67-75. PubMed ID: 11490527
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of adynamic bone disease in dialyzed patients.
    Malluche HH; Monier-Faugere MC
    Kidney Int Suppl; 1992 Oct; 38():S62-7. PubMed ID: 1405383
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Frequency of adynamic bone disease and aluminum storage in Italian uraemic patients--retrospective analysis of 1429 iliac crest biopsies.
    Ballanti P; Wedard BM; Bonucci E
    Nephrol Dial Transplant; 1996 Apr; 11(4):663-7. PubMed ID: 8671855
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Aluminum and uremic bone disease. Diagnostic utility of serum aluminum and the deferoxamine (DFO) test ].
    Jarava C; Armas JR; Palma A
    Nefrologia; 2001; 21(2):174-81. PubMed ID: 11464651
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adynamic bone disease: pathogenesis, diagnosis and clinical relevance.
    Mucsi I; Hercz G
    Curr Opin Nephrol Hypertens; 1997 Jul; 6(4):356-61. PubMed ID: 9263684
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Iron overload and bone disease in chronic dialysis patients.
    Van de Vyver FL; Visser WJ; D'Haese PC; De Broe ME
    Nephrol Dial Transplant; 1990; 5(9):781-7. PubMed ID: 2129351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aluminum-associated bone disease in chronic renal failure: high prevalence in a long-term dialysis population.
    Andress DL; Maloney NA; Endres DB; Sherrard DJ
    J Bone Miner Res; 1986 Oct; 1(5):391-8. PubMed ID: 3503554
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of adynamic bone in patients with secondary hyperparathyroidism after intermittent calcitriol therapy.
    Goodman WG; Ramirez JA; Belin TR; Chon Y; Gales B; Segre GV; Salusky IB
    Kidney Int; 1994 Oct; 46(4):1160-6. PubMed ID: 7861712
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk factors for renal osteodystrophy: a multivariant analysis.
    Pei Y; Hercz G; Greenwood C; Segre G; Manuel A; Saiphoo C; Fenton S; Sherrard D
    J Bone Miner Res; 1995 Jan; 10(1):149-56. PubMed ID: 7747622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of intact, midregion, and carboxy terminal assays of parathyroid hormone for the diagnosis of bone disease in hemodialyzed patients.
    Solal ME; Sebert JL; Boudailliez B; Marie A; Moriniere P; Gueris J; Bouillon R; Fournier A
    J Clin Endocrinol Metab; 1991 Sep; 73(3):516-24. PubMed ID: 1874930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.